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Abstract
Aims: To describe the characteristics of infective endocarditis (IE) after transcatheter aortic valve implanta-
tion (TAVI).
Methods and results: This study was performed using the GAMES database, a national prospective reg-
istry of consecutive patients with IE in 26 Spanish hospitals. Of the 739 cases of IE diagnosed during the 
study, 1.3% were post-TAVI IE, and these 10 cases, contributed by five centres, represented 1.1% of the 952 
TAVIs performed. Mean age was 80 years. All valves were implanted transfemorally. IE appeared a median 
of 139 days after implantation. The mean age-adjusted Charlson comorbidity index was 5.45. Chronic kid-
ney disease was frequent (five patients), as were atrial fibrillation (five patients), chronic obstructive pulmo-
nary disease (four patients), and ischaemic heart disease (four patients). Six patients presented aortic valve 
involvement, and four only mitral valve involvement; the latter group had a higher percentage of prosthetic 
mitral valves (0% vs. 50%). Vegetations were found in seven cases, and four presented embolism. One patient 
underwent surgery. Five patients died during follow-up: two of these patients died during the admission in 
which the valve was implanted.
Conclusions: IE is a rare but severe complication after TAVI which affects about 1% of patients and entails 
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SAVR surgical aortic valve replacement
TAVI transcatheter aortic valve implantation
Introduction
Prosthetic valve endocarditis is a severe complication which often 
entails dramatic clinical consequences owing to its high morbid-
ity and mortality rates1. In the case of the aortic valve, this dis-
ease affects up to 10-15% of patients after prosthetic valve surgery 
and frequently necessitates reintervention2. During the last few 
years, transcatheter aortic valve implantation (TAVI) has emerged 
as an attractive and feasible alternative for the treatment of severe 
aortic stenosis in symptomatic patients with high surgical risk. 
Recent multicentre trials have demonstrated that the two most com-
monly used TAVI systems – the Edwards SAPIEN valve (Edwards 
Lifesciences, Irvine, CA, USA) and the CoreValve® (Medtronic, 
Minneapolis, MN, USA) – are both safe and effective3,4. The trans-
femoral approach is the most frequent and is suitable for both types 
of valve. Success rates greater than 90% have been reported, as 
have 30-day procedural mortality rates lower than 10%5. Most 
complications after TAVI are technical and device-related, includ-
ing significant periprosthetic paravalvular leaks6 and conduction 
disturbances7. In the absence of complications, survival and out-
come are expected to be similar to those of patients without aortic 
stenosis8. Moreover, these prosthetic valves have good haemody-
namic characteristics in the short and medium terms6.
Infective endocarditis (IE) is a potentially severe complication 
of TAVI9, with only a few cases described in the literature to date10-
29. The incidence of this entity in large TAVI cohorts ranges between 
0% and 2.3% after one to three years of follow-up14-18. TAVI valves 
are implanted mainly in elderly patients with frequent comorbidities 
in whom IE could entail a worse prognosis. Moreover, many of the 
patients with TAVI are inoperable, thus limiting options for treatment 
of IE. We aimed to review and describe the clinical and echocardio-
graphic characteristics of patients with this disease and to determine the 
prognostic factors related to this uncommon post-TAVI complication.
Methods
We used the GAMES (Grupo de Apoyo al Manejo de la EndocarditiS 
[Management of Endocarditis Support Group]) database, a Spanish 
national prospective registry of consecutive patients with IE30 
recruited from 26 Spanish hospitals between January 1, 2008, and 
December 31, 2013. IE was defined according to the modified Duke 
criteria31. Multidisciplinary teams completed a standard case report 
form. Regional and local ethics committees approved the study, and 
patients gave their informed consent. Five centres contributed the 
10 cases of IE after TAVI.
TAVI PROCEDURE
All patients were pre-treated with aspirin and clopidogrel. Heparin 
was administered during the procedure in order to maintain an acti-
vated clotting time above 250 s. The procedures were performed 
under general anaesthesia and with the aid of fluoroscopy and trans-
oesophageal echocardiography to ensure accurate valve deploy-
ment. The stenotic valve was predilated with an undersized balloon 
to facilitate implantation, and the valve was placed during rapid 
pacing in the right ventricle or epicardium. If necessary, additional 
post-dilation was performed in cases of relevant paravalvular regur-
gitation. None of the patients presented a fever 48 hrs before valve 
implant, and all had a normal leukocyte count on the day of TAVI.
All patients with IE after TAVI were included, irrespective of 
valve location. An extensive number of variables was registered, 
including baseline clinical characteristics, procedural character-
istics and valve model, presence of predisposing factors for IE, 
laboratory markers, and echocardiographic and microbiological 
findings (blood cultures). Follow-up (all patients) included treat-
ment performed (type of antibiotics, surgery), complications related 
to IE, death, and cause of death. IE was classified as possible or 
definite. We also compared IE after TAVI with IE after surgical aor-
tic valve replacement (SAVR), in the same period. The study was 
approved by the Ethics Committee of the Hospital Universitario 
Gregorio Marañón, Madrid, Spain.
Statistical analysis
Quantitative variables were expressed as mean±SD; qualitative 
variables were expressed as numbers and percentages. Continuous 
variables were compared using the t-test, and categorical variables 
were compared using the chi-square test or Fisher’s exact test when 
the chi-square test was not appropriate.
Results
We identified 10 cases of IE after TAVI in our series. Of the 952 
TAVIs performed, 650 (68.3%) were CoreValve (610 transfemoral, 
40 subclavian) and 302 (31.7%) Edwards SAPIEN (144 transapi-
cal, 158 transfemoral). A total of 1.1% were complicated by IE. 
Of the 739 cases of IE diagnosed during the study, 10 (1.3%) were 
post-TAVI IE and 221 (29.9%) post SAVR.
Table 1 shows the characteristics of the 10 patients. Mean age was 
80 years (range, 69-87 years) and six were men (60%). Nine patients 
received a CoreValve prosthesis and one an Edwards SAPIEN valve 
(patient 5). All valves were implanted transfemorally. Endocarditis 
appeared a median of 139 days after implantation. Comorbidity 
was high, with a mean age-adjusted Charlson comorbidity index of 
5.45. The most common underlying conditions included moderate or 
severe chronic kidney disease (five patients), atrial fibrillation (five 
patients), chronic obstructive pulmonary disease (four patients), and 
ischaemic heart disease (four patients).
Six patients (patients 1 to 6) had IE in the aortic valve (TAVI 
endocarditis), and four (patients 7 to 10) presented only mitral 
valve involvement. When we compared patients with TAVI endo-
carditis and patients with exclusively mitral involvement, the only 
difference was that the latter group had a higher percentage of pros-
thetic mitral valves (0% vs. 50%). These mitral valves had been 
implanted 17 years before TAVI in one case (patient 7) and 25 years 
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IE was definite in all cases except patient 10 (possible IE). All 
patients had fever and elevated C-reactive protein levels (range, 
5.6-33.3 mg/L). IE-related vascular findings were detected in only 
one patient, who presented petechiae (patient 3). Mitral regurgi-
tation due to IE was present in three patients (patient 6, severe; 
patient 9, mild; and patient 10, moderate). Patient 8 had severe 
mitral regurgitation before IE in the aortic valve.
All blood cultures were positive. The pathogens identified and 
antibiotic treatment administered are shown in Table 1. Gram-
positive microorganisms predominated, as follows: Enterococcus 
faecalis (three), Streptococcus viridans or Granulicatella adiacens 
(three), and Staphylococcus epidermidis (one). Less common aeti-
ologies were detected in the remaining three cases: Acinetobacter 
species, Salmonella Enteritidis, and Candida parapsilosis (one 
each). These three episodes occurred significantly earlier after 
TAVI (24 vs. 250 days).
Six patients presented nosocomial or healthcare-related IE 
(patients 1, 2, 5, 6, 7, and 10). The origins of IE were endovascular 
catheter (three patients), genitourinary tract (one patient), gastroin-
testinal tract (one patient), oral cavity (one patient), and unknown 
(four patients). Patients 4 and 7 also underwent urinary catheterisa-
tion before IE.
Transthoracic echocardiography was performed in all patients; 
transoesophageal echocardiography was performed in nine patients 
(not performed in patient 9, since IE was diagnosed with transtho-
racic echocardiography). Vegetations were demonstrated in seven 
cases (echocardiography findings are summarised in Table 1). Four 
patients presented systemic embolism: patients 1, 9, and 10 pre-
sented splenic embolism (with splenic abscess in patient 1); patient 9 
also presented kidney embolism and abscess, and patient 7 pre-
sented central nervous system ischaemia not related to IE. Patient 6 
presented peripheral arterial embolism. Renal function worsened in 
five patients, and three patients presented heart failure.
After multidisciplinary assessment, surgery was indicated in 
five patients, although it was only performed in patient 2, owing to 
technical difficulties or severe comorbidity which rendered surgery 
impossible in the remaining four. Patient 2 was readmitted 117 days 
after TAVI due to worsening heart failure, and IE was diagnosed 
during admission. The patient successfully underwent reparative 
surgery of the aortic root but was admitted eight days after being 
discharged owing to symptomatic high-degree atrioventricular 
block and refractory heart failure. The patient died 11 days later. 
A total of five patients died during follow-up. Patients 4 and 7 died 
during the admission in which the valve was implanted.
The comparison of the clinical characteristics of patients with IE 
after TAVI to patients with IE after SAVR is depicted in Table 2. 
TAVI patients presented a more advanced age but had similar one-
year mortality.
Discussion
Our results show that IE is a rare but severe complication in patients 
undergoing TAVI. It affects about 1% of patients and has a rela-
tively high mortality rate, reaching 50% during follow-up (five out 
Table 2. Comparison of clinical characteristics in 10 patients with 
infective endocarditis after TAVI to 221 patients with IE after 
surgical aortic valve replacement.
TAVI (N=10) AVR (N=221) p-value
Age (mean, interquartile range) 79.5 (77.2-86.0) 73.0 (63.0-78.0) 0.001
Male sex (%) 6 (60.0) 149 (67.7) 0.610
Months from procedure (mean, 
interquartile range)
3.5 (1-10.2) 17 (3-69.5) 0.012
Aetiology (%) Staphylococcus 1 (10.0) 92 (41.8) 0.045
Streptococcus 2 (20.0) 37 (16.7) 0.788
Enterococcus 3 (30.0) 35 (15.8) 0.237
Unknown 0 27 (12.2) 0.240
Aortic valve vegetation (%) 3 (30.0) 87 (39.4) 0.552
Complications (%) Valve rupture 1 (10.0) 6 (2.5) 0.498
Abscess 1 (10.0) 79 (34.2) 0.042
Pseudoaneurysm 2 (20.0) 11 (4.7) 0.194
Fistula 0 12 (5.2) 0.415
Antibiotics (%) Aminoglycosides 2 (20.0) 133 (60.2) 0.012
Vancomycin 0 114 (51.6) 0.001
Beta-lactams 7 (70.0) 117 (52.9) 0.290
1-year mortality (%) 4 (40.0) 95 (43.0) 0.852
of ten). In our study, IE was recorded during the first year after 
TAVI in nine of the 10 patients and during the first month in three. 
Two patients died during the admission in which the valve was 
implanted. Four patients presented only mitral valve IE, two of 
them in a metallic prosthesis.
The prevalence of IE patients receiving TAVI seems to be similar 
to that of patients undergoing open aortic valve surgery, as pros-
thetic valve endocarditis after surgical replacement has been esti-
mated to occur at a rate of 0.3% to 1% per patient-year2. In the 
Placement of AoRtic TraNscathetER Valves (PARTNER) cohort B 
trial3, the incidence of IE at two years was similar in both groups 
(1.5% in the TAVI group and 1.0% in the surgery group). After open 
aortic valve surgery, IE is associated with poor prognosis and high 
rates of morbidity, reintervention, and mortality2. Prognosis seems 
to improve with timely surgical intervention and close follow-up32.
TAVI has proven to be a safe and effective alternative to conven-
tional aortic valve surgery, especially in patients with high surgical 
risk33,34. IE following TAVI is a rare but severe complication, with 
few previously reported cases10-29 (Table 3). The vast majority of 
cases occur during the first year after TAVI. In an autopsy study, 
Loeser et al10 studied 13 patients after TAVI and found three cases 
of acute IE (23%); the patients died one, three, and 14 days after the 
procedure. Interestingly, the endocarditis was not identified while 
the patient was alive, suggesting that many cases of post-TAVI IE 
go undiagnosed. In their single-centre series of four cases of post-
TAVI IE with a definite diagnosis and one with a possible diagnosis, 
Puls et al23 also concluded that it might be particularly difficult to 
diagnose IE after TAVI. In our series, the mean time between TAVI 








IE 20 days after TAVI, with blood cultures that were positive for 
Candida. Early IE due to Candida after TAVI was reported28 in 
a 91-year-old man who had previously undergone TAVI with an 
Edwards SAPIEN transapical valve and developed septic shock. He 
died 54 days after TAVI. Staphylococci, fungi, and Gram-negative 
bacilli are the main causes of early prosthetic valve endocarditis 
(<12 months after implantation) in studies of surgical prostheses35. 
In our series, IE was detected during the first year after implanta-
tion, except in patient 8, who developed mitral valve IE caused by 
S. viridans. A possible explanation for the early onset of IE is that 
TAVI is usually performed in the catheterisation laboratory, as most 
centres do not have a so-called hybrid room. Consequently, the risk 
of early infection increases, since the disinfection and sterilisation 
criteria are not as stringent in the catheterisation laboratory as in 
the operating room. In addition, since elderly patients with comor-
bidities are less immunocompetent, the incidence of bacteraemia is 
higher in TAVI patients.
Different types of infective complication have been recorded. 
In their single-centre study, Onsea et al36 retrospectively assessed 
the number of infective complications in patients undergoing 
TAVI between 2008 and 2011. Eleven of 73 patients developed 
a post-procedural infection, but only one case was attributed to 
the procedure itself (infection of a surgical groin scar), as most 
were related to urinary tract and bronchopulmonary infections. 
The authors found no cases of IE and no positive blood cul-
tures, and concluded that TAVI in a catheterisation laboratory is 
not associated with an increased risk of infective complications. 
In the transfemoral approach, groin access-site infections seem 
to be rare36, although obesity has been associated with a higher 
incidence of transapical access site infection37. In any case, local 
infections do not seem to entail worse prognosis and are not 
clearly associated with IE. As for height of implantation, it has 
been suggested that, when implanted too low, the infected pros-
thesis can enter into contact with the anterior mitral valve leaflet, 
thus facilitating formation of aneurysms11,12. Furthermore, resid-
ual paravalvular leak, which is not uncommon after TAVI6, has 
been suggested to predispose to IE23, as have advanced age and 
the presence of comorbidities.
Table 3. Characteristics of 25 cases of infective endocarditis (IE) in patients with transcatheter aortic valve implantation (TAVI) 
previously reported in the literature.
Aetiological agent
Months from  
TAVI to IE
Surgery Outcome Type of valve Access Reference
Not specified Postoperatively No Death Edwards SAPIEN Transapical 10
Methicillin-resistant Staphylococcus aureus 0.5 No Death Edwards SAPIEN Transapical 10
Not specified Postoperatively No Death Edwards SAPIEN Transapical 10
Streptococcus viridans 6 No Good CoreValve Left subclavian 11
Enterococcus faecalis 3 No Death Edwards SAPIEN Transapical 13
Corynebacterium 4 Yes Good CoreValve Transfemoral 14
Histoplasma capsulatum 9 Yes Good Edwards SAPIEN Transfemoral 15
Moraxella nonliquefaciens 2 No Good CoreValve Transfemoral 16
Staphylococcus lugdunensis 19 No Death CoreValve Transfemoral 17
Streptococcus anginosus 11 Yes Good Edwards SAPIEN Transfemoral 18
Staphylococcus aureus 4 No Good CoreValve Transfemoral 19
Enterococcus faecium 4 No Good CoreValve Transfemoral 20
Not specified 12 Yes Good Edwards SAPIEN Transfemoral 21
Staphylococcus epidermidis 3 No Good CoreValve Transfemoral 22
Methicillin-resistant Staphylococcus aureus 7 No Death CoreValve Transfemoral 23
Enterococcus faecalis 3 No Good Edwards SAPIEN Transapical 23
Enterococcus faecalis 9 No Good Edwards SAPIEN Transapical 23
Escherichia coli 5 No Death Edwards SAPIEN Transfemoral 23
Streptococcus gordonii 23 No Good Edwards SAPIEN Transapical 23
Streptococcus anginosus 12 Yes Good Edwards SAPIEN Transfemoral 24
Staphylococcus haemolyticus 7 No Good CoreValve Transfemoral 25
Staphylococcus epidermidis 5 No Death Edwards SAPIEN Transfemoral 
(valve-in-valve)
26
Enterococcus faecalis 6 Yes Good Edwards SAPIEN Transapical 27
Candida albicans Postoperatively No Death Edwards SAPIEN Transapical 28











In our series, all patients presented with fever, elevated C-reactive 
protein, and positive blood cultures; therefore, our data highlight 
the importance of obtaining microbiological samples before start-
ing empiric antimicrobial therapy in patients with previous TAVI 
and fever. Samples should be taken irrespective of the presence of 
valve murmurs. In fact, no new or different valve murmurs were 
detected in the physical examination on admission in any of our 
patients. Positron emission tomography and computed tomography 
(PET/CT) were not performed in our patients. Although PET/CT is 
currently not sufficiently adequate for the diagnosis of IE because 
of its low sensitivity38, improvements such as patient preparation 
and technical advances may increase its sensitivity, and this tech-
nique could have an important role in the future.
As expected, patients from our series were elderly and presented 
frequent comorbidities, findings that are consistent with the obser-
vation that TAVI is mostly performed in those with high surgical 
risk. As comorbidity is an independent predictor of poor progno-
sis in patients with IE39, high mortality is to be expected. Chronic 
kidney disease and heart failure are important predictors of poor 
prognosis in patients with prosthetic valve IE32; both were frequent 
in our series. Two of the three patients with worsening heart fail-
ure eventually died. Most patients in such situations are considered 
inoperable, probably because of their poor prognosis. Moderate-
severe chronic kidney disease was present in five patients, and three 
finally died.
Five patients in our series died during follow-up: in two cases, 
death was because of complications clearly related to IE. The 
remaining patients presented non-cardiac causes of death. Surgery 
was only performed in one patient, although it was considered indi-
cated after multidisciplinary assessment in five cases. In elderly 
patients with IE after open aortic valve replacement, surgical inter-
vention may be life-saving40. However, TAVI is mostly performed 
in elderly patients with frequent comorbidity and high or even pro-
hibitive surgical risk, and this could explain why most patients were 
treated conservatively. In spite of this fact, in our series, one-year 
mortality was similar in patients with IE after TAVI and in those 
with IE after SAVR (Table 2).
Nine of our ten patients with IE received a CoreValve TAVI; 
however, the Edwards SAPIEN valve was only used in about a third 
of our patients. Our data are insufficient to determine if one valve 
type is more prone to IE. TAVI with the CoreValve has a higher 
rate of atrioventricular block and permanent pacemaker implanta-
tion than with an Edwards SAPIEN7, and this could be a factor con-
cerning IE development. On the other hand, from the 25 previously 
reported IE after TAVI (Table 3), only nine (36%) were in patients 
who received a CoreValve. Again, this could be related to the higher 
use of one valve type in those institutions.
Little is known about therapy of IE in TAVI. When the disease is 
suspected, a multidisciplinary approach should be adopted in order 
to ensure correct diagnosis and treatment. Prophylaxis should be tai-
lored to the patient. The Valve Academic Research Consortium has 
recommended reporting IE as an individual endpoint41 after TAVI, 
although prophylaxis of endocarditis before TAVI is not mandatory 
and often depends on hospital preferences and protocols. Both our 
findings and those reported in the literature show that post-TAVI IE 
is a severe complication for which adequate prophylaxis must be 
considered before invasive procedures and during follow-up11. In 
addition, special attention ought to be paid when performing proce-
dures that might cause bacteraemia, including catheter management 
and catheterisation.
To our knowledge, this is the first multicentre series to analyse 
IE after TAVI. Our results show that IE is a rare but severe com-
plication which affects about 1% of patients undergoing TAVI and 
has a relatively high mortality rate, reaching 50% during follow-up 
(five out of ten). In nine of our 10 patients, IE occurred during the 
first year after TAVI. Further studies are needed to improve man-
agement of such a feared complication.
Impact on daily practice
More emphasis should be placed on disinfection and sterilisa-
tion in the catheterisation laboratory, with strict hygiene and 
specific staff education similar to that provided for the operat-
ing room. High-efficiency particulate air filtered laminar airflow 
and criteria regarding air control would be welcome. Moreover, 
in many TAVI patients, IE is nosocomial, that is, secondary to 
invasive techniques, such as endovascular or urinary tract cath-
eterisation, which should be performed with extreme care. 
Patients should be more closely monitored during the first year 
after TAVI, and physicians should have a low threshold of suspi-
cion. Echocardiography and blood culture are key approaches in 
patients with IE.
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